The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Sam Slutsky - LifeSci Capital LLC - Analyst
: Hey, good morning, everyone. Thanks for taking the question. Just a couple. Could you just refresh us on the top-line epidemiology as you think
about AML and MDS versus ALL? And then kind of on the CD45 program you mentioned, obviously, that expands the patient population. Just kind
of walk through that and then how far behind that program is versus the initial pivotal.
Question: Sam Slutsky - LifeSci Capital LLC - Analyst
: Got it. And then how far behind do you think the CD45 program is in terms of when you might go to get that into a pivotal study?
Question: Sam Slutsky - LifeSci Capital LLC - Analyst
: Okay, thanks.
Question: Maxwell Skor - Morgan Stanley & Co Ltd - Analyst
: Great, thank you. Thank you for taking my question. Are you able to hear me?
Question: Maxwell Skor - Morgan Stanley & Co Ltd - Analyst
: Okay, great. Was there a specific threshold of T cell expansion associated with relapse or prolonged incomplete chimerism? And also, how did you
settle on a lentiviral-based platform for your in vivo engineering of T cells? Any consideration or additional color just around vetting other approaches
and why do you think lenti is the best path forward? Thank you.
Question: Maxwell Skor - Morgan Stanley & Co Ltd - Analyst
: Great. Thank you very much.
Question: David Nierengarten - Wedbush Securities Inc - Analyst
: Thanks for taking the questions. First, I don't have the slide up in front of me right now. Is there an interim look planned for the pivotal study in
AML and MBS for 101 as you start enrolling that? And then the second one, back to the T cell question, is there any other quality control? Or is that
the right word for making sure the product in the pivotal study is the appropriate product for those patients? Thanks.
Question: David Nierengarten - Wedbush Securities Inc - Analyst
: Sorry, is there a plan?
Question: David Nierengarten - Wedbush Securities Inc - Analyst
: Thanks.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 03, 2025 / 1:00PM, TCRX.OQ - TScan Therapeutics Inc Update Call
Question: Nicholas Lorusso - Cowen and Company LLC - Analyst
: Can you hear me now? This is Nick on for Tara. There we go.
Question: Nicholas Lorusso - Cowen and Company LLC - Analyst
: All right, great. Sorry about that. I just have two. So the first one is, what was your findings from the Phase 1 ALLOHA trial? Or I guess more so, what's
the hypothesis that you guys have for why the increased or the high levels of expansion led to this relapse in some patients? And then the second
one is, how has the powering changed in the pivotal trial given the requirement for the internal control arm? Thank you.
Question: Nicholas Lorusso - Cowen and Company LLC - Analyst
: Thank you very much.
| 
